| Literature DB >> 35268075 |
Enric Sánchez1, Mohsen Kerkeni2, Marta Hernández1, Ricard Gavaldà3, Ferran Rius1, Ariadna Sauret1, Gerard Torres4, Marcelino Bermúdez-López5,6, Elvira Fernández5,6, Eva Castro-Boqué5,6, Francisco Purroy7, Dídac Mauricio8,9, Cristina Farràs-Sallés10, Miquel Buti10, Pere Godoy7, Reinald Pamplona11, Albert Lecube1,9.
Abstract
A large body of evidence demonstrates a relationship between hyperglycemia and increased concentrations of advanced glycation end-products (AGEs). However, there is little information about subcutaneous AGE accumulation in subjects with prediabetes, and whether or not this measurement could assist in the diagnosis of prediabetes is unclear. A cross-sectional study was conducted in 4181 middle-aged subjects without diabetes. Prediabetes (n = 1444) was defined as a glycosylated hemoglobin (HbA1c) level between 39 and 47 mmol/mol (5.7 to 6.4%), and skin autofluorescence (SAF) measurement was performed to assess AGEs. A multivariable logistic regression model and receiver operating characteristic curve were used. The cohort consisted of 50.1% women with an age of 57 [52;62] years, a BMI of 28.3 [25.4;31.6] kg/m2, and a prevalence of prediabetes of 34.5%. Participants with prediabetes showed higher SAF than control participants (2.0 [1.7;2.2] vs. 1.9 [1.7;2.2], p < 0.001). However, HbA1c was not significantly correlated with SAF levels (r = 0.026, p = 0.090). In addition, the SAF level was not independently associated with prediabetes (OR = 1.12 (0.96 to 1.30)). Finally, there was no good cutoff point for SAF to identify patients with prediabetes (AUC = 0.52 (0.50 to 0.54), sensitivity = 0.61, and 1-specificity = 0.56). Given all of this evidence, we can conclude that although there is an increase in SAF levels in participants with prediabetes, the applicability and clinical relevance of the results is low in this population.Entities:
Keywords: advanced glycation end-products; glycosylated hemoglobin; prediabetes; skin autofluorescence
Mesh:
Substances:
Year: 2022 PMID: 35268075 PMCID: PMC8912766 DOI: 10.3390/nu14051102
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram for the study population.
Main clinical characteristics of the study population according to glucose abnormalities.
| Prediabetes ( | Control Group ( | |
|---|---|---|
| Age (years) | 59 [54; 64] | 56 [52; 62] |
| Women, | 827 (57.3) | 1268 (46.3) |
| BMI (kg/m2) | 29.5 [26.7; 33.1] | 27.7 [24.8; 30.8] |
| HbA1c (mmol/mol) | 40 [39; 42] | 36 [33; 37] |
| HbA1c (%) | 5.8 [5.7; 6.0] | 5.4 [5.2; 5.5] |
| Hypertension, | 684 (47.4) | 992 (36.2) |
| Dyslipidemia | 865 (59.9) | 1363 (49.8) |
| Obesity, | 581 (40.2) | 758 (27.7) |
| Current or former smoker, | 828 (57.3) | 1819 (66.5) |
Data are presented as a median [interquartile range] or n (percentage). HbA1c: glycated hemoglobin; BMI: body mass index.
Figure 2Plot displaying the skin autofluorescence value according to the presence prediabetes.
The multivariable logistic regression model for presence of prediabetes.
| Prediabetes | OR (95% CI) | ||
|---|---|---|---|
| Sex | Women | Reference | |
| Men | 1.34 (1.16 to 1.55) | <0.001 | |
| Age (years) | 1.04 (1.03 to 1.05) | <0.001 | |
| Body mass index (kg/m2) | 1.09 (1.07 to 1.10) | <0.001 | |
| Smoking status | Never | Reference | |
| Current or former | 1.08 (0.93 to 1.25) | 0.326 | |
| Skin autofluorescence (AU) | 0.97 (1.00 to 0.85) | 0.969 | |
| Hosmer–Lemeshow test of fit | 0.65 (0.64 to 0.67) | 0.002 | |
| Area under the ROC curve | |||
Figure 3Receiver operating characteristic (ROC) curve analysis to evaluate the accuracy of skin autofluorescence in distinguishing prediabetes from cases with normal metabolism, together with sensitivity/specificity data.